

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 16, 2023**

---

**LIANBIO**

(Exact name of registrant as specified in its charter)

---

**Cayman Islands**  
(State or other jurisdiction  
of incorporation)

**001-40947**  
(Commission  
File Number)

**98-1594670**  
(IRS Employer  
Identification No.)

**103 Carnegie Center Drive, Suite 309**  
**Princeton, NJ**  
(Address of principal executive offices)

**08540**  
(Zip Code)

**(Registrant's telephone number, including area code): (609) 486-2308**

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>American depositary shares, each representing 1 ordinary share, \$0.000017100448 par value per share</b>	<b>LIAN</b>	<b>The Nasdaq Global Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---



## **Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Compensatory Arrangements of Certain Officers.**

### *Departure of Chief Executive Officer*

On December 19, 2023, LianBio (the “Company”) announced that Yizhe Wang, the Company’s Chief Executive Officer and member of the Company’s board of directors (the “Board”), has decided to resign as Chief Executive Officer and as a member of the Board, effective December 16, 2023, to pursue other business and professional interests and opportunities. The Company thanks Dr. Wang for his many contributions to the growth and success of the business during his tenure with the Company.

On December 16, 2023, the Company entered into a separation agreement with Dr. Wang (the “Separation Agreement”), pursuant to which Dr. Wang will be entitled to the following benefits:

- 60 days’ pay in lieu of notice at his final base rate of pay;
- Severance payment in the amount of \$1,525,000 in equal installments twice per month for one (1) year beginning on January 1, 2024 and subsidized COBRA payments for up to 12 months; and
- Accelerated vesting for a portion of his outstanding options and RSUs and the extension of the exercise period for a portion of his vested options.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the period ending on December 31, 2023.

### *Appointment of Interim Chief Executive Officer*

In connection with Dr. Wang’s departure, effective December 16, 2023, the Board appointed Adam Stone, member of the Board, as Interim Chief Executive Officer of the Company, until his successor is appointed or his earlier death, resignation or removal.

Mr. Stone (44) has served as a member of our Board since October 2019. Since July 2021 and February 2021, respectively, Mr. Stone has served as the Chief Executive Officer of ARYA Sciences Acquisition Corp V and ARYA Sciences Acquisition Corp IV, respectively, and as a member of their boards of directors. Mr. Stone has also served as a member of the boards of directors of Solid Biosciences since November 2015 and Immatix since July 2020. Mr. Stone also serves on the board of directors of Xontogeny LLC. Mr. Stone previously served as the chief executive officer and a member of the board of directors of ARYA Sciences Acquisitions Corps I, II, and III. Mr. Stone joined Perceptive, a life sciences focused investing firm and affiliate of the Company, in 2006 and has served as Chief Investment Officer since 2012 and is a member of the internal investment committees of Perceptive’s credit opportunities and venture funds. Mr. Stone previously served as a Senior Analyst at Ursus Capital from 2001 to 2006, where he focused on biotechnology and specialty pharmaceuticals. Mr. Stone has also served as a member of the boards of directors of Solid Biosciences since November 2015 and Immatix since July 2020. Mr. Stone earned a bachelor’s degree in molecular biology from Princeton University.

Mr. Stone will remain as a director of the Company. No formal employment agreement has been entered into between Mr. Stone and the Company, and Mr. Stone will not be compensated for his service as the Interim Chief Executive Officer of the Company.

There are no family relationships between Mr. Stone and any director, executive officer or nominee thereof of the Company. There are no related party transactions between the Company and Mr. Stone that would require disclosure under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

## **Item 7.01. Regulation FD Disclosure**

A copy of the press release announcing the above-described management changes is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	<a href="#">Press release issued by LianBio, dated December 19, 2023</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LIANBIO**

By: /s/ Brianne Jahn

\_\_\_\_\_  
Brianne Jahn

Chief Business Officer

Date: December 19, 2023



## LianBio Announces Departure of Chief Executive Officer

**Shanghai and Princeton, N.J.**, December 19, 2023 - LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities.

In connection with his departure, the LianBio Board of Directors has appointed Adam Stone, Chief Investment Officer of Perceptive Advisors and member of the LianBio Board of Directors as Interim Chief Executive Officer.

“Under Yizhe’s leadership, LianBio built a comprehensive cross-border platform for drug development, advanced multiple programs into pivotal Phase 3 trials, developed a commercial launch infrastructure designed to maximize patient access to innovative new medicines, and executed transformative strategic transactions,” said Konstantin Poukalov, Executive Chairman of the LianBio Board of Directors. “I thank Yizhe for his many contributions to LianBio and look forward to partnering with him on his future endeavors.”

LianBio’s Board of Directors will continue to represent the best interests of LianBio and its shareholders and evaluate strategic alternatives for the Company. The Board of Directors expects to communicate an update on the ongoing strategic review in the first quarter of 2024.

### About LianBio

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For additional information, please visit the company’s website at [www.lianbio.com](http://www.lianbio.com).

### For investor inquiries, please contact:

Elizabeth Anderson, VP Communications and Investor Relations

E: [elizabeth.anderson@lianbio.com](mailto:elizabeth.anderson@lianbio.com)

T: (646) 655-8390

### For media inquiries, please contact:

Katherine Smith, Evoke Canale

E: [katherine.smith@evokegroup.com](mailto:katherine.smith@evokegroup.com)

T: (619) 849-5378